-
Moderna says COVID-19 vaccine 94.5% effective
"This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease," said Stephane Bancel, Moderna's CEO.
-
Moderna's COVID-19 vaccine shows similar immune response in old and young
Moderna is now reporting interim data from the Phase I study that includes analysis from 20 additional people and details on how the vaccine performs in older people.
-
Moderna, Pfizer start decisive COVID-19 vaccine trials, eye year-end launches
The trials, both announced on Monday, are the first late-stage studies supported by the Trump administration’s effort to speed development of measures against the novel coronavirus.
-
Moderna's COVID-19 vaccine candidate moves into late-stage trial
The large late-stage trial is designed to evaluate the safety of Moderna’s mRNA-1273 and determine if the vaccine can prevent symptomatic COVID-19 after two doses.
-
Wave of promising study results raise hopes for coronavirus vaccines
Whether any of these efforts will result in a vaccine capable of protecting billions of people and ending the global pandemic that has claimed more than 600,000 lives is still far from clear.
-
COVID-19 vaccine hopes raised by fresh trials
The studies are the latest to inspire hopes of developing a vaccine after nearly 600,000 deaths and 13.4 million cases worldwide since the outbreak began in China last year.
-
Millions worldwide back in virus confinement, but hope on US vaccine
With countries and cities across the globe reimposing restrictions in the face of new outbreaks of the disease, infections in India have continued to soar.
